Scavilla Daniel T 4
4 · DENTSPLY SIRONA Inc. · Filed Mar 6, 2026
Research Summary
AI-generated summary of this filing
DENTSPLY SIRONA (XRAY) CEO Daniel Scavilla Receives Award
What Happened
Daniel T. Scavilla, President, CEO and director of DENTSPLY SIRONA Inc. (XRAY), was granted equity awards on 2026-03-04 totaling 2,211,689 shares. The grant breaks down into 145,089 restricted stock units (RSUs) and 2,066,600 derivative awards (stock options). Both grants show $0 cash paid at acquisition (typical for compensation/awards).
Key Details
- Transaction date: 2026-03-04; Form 4 filed 2026-03-06 (timely filing).
- Grants: 145,089 RSUs (acquired @ $0) and 2,066,600 derivative awards/options (acquired @ $0).
- Reported acquisition value: $0 (these are compensation awards, not open‑market purchases).
- Shares owned after the transaction: not specified in the provided filing summary.
- Footnotes:
- F1: RSUs vest in annual one‑third increments over three years, ending March 4, 2029.
- F2: Stock options vest in annual one‑third increments over three years (ending March 4, 2029) with an exercise price equal to 115% of the closing price on the grant date.
- Filing accession: 0000818479-26-000101.
Context
These grants are compensation awards rather than purchases or sales. RSUs convert to shares as they vest (over three years); the stock options require the share price to exceed the 115% strike price before they have intrinsic value. Such awards are common for senior executives and do not by themselves indicate immediate buying or selling activity.
Insider Transaction Report
- Award
Common Stock
[F1]2026-03-04+145,089→ 161,839.066 total - Award
Stock Option (Right to Buy)
[F2]2026-03-04+2,066,600→ 2,066,600 totalExercise: $15.46From: 2027-03-04Exp: 2036-03-04→ Common Stock (2,066,600 underlying)
Footnotes (2)
- [F1]Award consists entirely of Restricted Stock Units (RSUs) which vest in annual one-third (1/3) increments over a three-year (3) period ending March 4, 2029.
- [F2]Stock options vest in annual one-third (1/3) increments over a three-year (3) period ending March 4, 2029, with an exercise price equal to 115% of the closing price of the Issuer's common stock as of the date of grant.